Kenjockety is focused on discovery and development of a new family of BsAbs with high tumor specificity. The foundational scientific concept is built around generating a library of functional mAbs (antagonists) to a unique set of drug resistant targets (efflux pumps) and pairing those mAbs with various known TAA targeted mAbs to engineer BsAb therapeutics for patients with drug resistant cancers. We are currently evaluating more than 70 BsAb constructs and have generated impressive in vivo proof of concept data in multiple tumor models that show potential for both combination and single agent approaches across a wide range of cancer indications. We have also done considerable work establishing our proprietary BASETM Platform and IP portfolio to support our efforts.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Oncology
Lead Product in Development:
KB1-1401 Bi-Specific Antibody
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
